招待演者／Invited Speakers

1981年	神戸大学医学部脳神経外科研修医
1987年	神戸大学大学院医学研究科修了（医学博士）
1987年～1988年	カリフォルニア大学サンフランシスコ校脳腫瘍研究センター　研究員
1988年～1994年	テキサス大学 M.D.アンダーソン癌センター神経腫瘍部門Assistant Professor
1994年～2006年	熊本大学医学部腫瘍医学講座　教授
2007年～2022年	慶應義塾大学医学部先端医科学研究所　遺伝子制御研究部門　教授
2015年～2021年	慶應義塾大学病院　副院長（臨床研究推進センター　センター長）
2022年～現在	藤田医科大学腫瘍医学研究センター　センター長兼特命教授
2023年～現在	藤田医科大学橋渡し研究シーズ探索センター　センター長

学会活動

日本癌学会理事長（2021年1月～2023年9月）
米国癌学会名誉会員
日本レックリングハウゼン病学会理事

受賞歴

2000年	The 4th Annual Hoshino Memorial Lecture Award, University of California, San Francisco, CA, USA
2000年	The 1st Victoria Jursnich Carhart Memorial Lecture Award, University of California, Irvine, CA, USA
2001年	The Deborah M. Richman Memorial Lectureship, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
2008年	第6回佐川がん特別研究助成賞
2020年	第29回日本癌学会　吉田富三賞
2020年	慶應義塾大学　福澤賞
2022年	第27回日本がん分子標的治療学会　鶴尾隆賞

INSTITUTION AND LOCATION	DEGREE	Completion Date	FIELD OF STUDY
Stanford University, Palo Alto, CA	BAS	06/1986	Philosophy and Biology
University of California, School of Medicine, San Francisco, CA	MD	12/1991	Medicine

Personal Statement

I am a neuropathologist with a research interest in the biological and clinical aspects of primary and metastatic brain tumors. I have experience with identification of biomarkers in brain tumors, including genomic studies. I have substantial involvement as a pathologist in the conduct of integral markers in clinical trials.

Chief of the Laboratory of Pathology at the National Cancer Institute in Bethesda, Maryland. In this role I endeavor to lead an effort to utilize molecular tools to change how we classify, understand and diagnose cancers in the clinic. I have an investigational interest in the use of molecular tools to classify brain tumors, including gliomas and meningiomas.

I have not published research or research product under any other name.

Ongoing and recently completed projects that I would like to highlight include:

• 1ZIABC011846　Aldape (PI) 2018 – 2023
  Single-cell DNA methylation analysis of human cancer
• 1ZIABC011847　Aldape (PI) 2017 – 2023
  Development and validation of a predictor of meningioma recurrence
• 1ZIABC011850　Aldape (PI) 2019 – 2023
  Genomic Biomarkers of Cancer

Positions, Scientific Appointments, and Honors

Positions and Employment

2018-present	Chief, Laboratory of Pathology, National Cancer Institute, Bethesda, MD
2018-present	Affiliate Scientist, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON
2018-present	Editor-in Chief (ad interim) Neuro-Oncology
2014-2018	Senior Scientist and Professor, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON
2012-2017	Executive editor, Neuro-Oncology
2012-2014	Department Chair, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
2007-2014	Professor, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
2001-2007	Associate Professor, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
1998-2001	Member, Biomedical Sciences Graduate Program, UCSF, San Francisco, CA
1995-2001	Assistant Professor, Department of Pathology, School of Medicine, UCSF, San Francisco, CA
1995-200	Member, Brain Tumor Research Center, UCSF, San Francisco, CA

Honors

2005-2011	Best Doctors in America
1990	Dean’s Prize for Medical Student Research, UCSF
1990	American Society of Clinical Pathologists’ Award for Academic Excellence and Achievement

Diversity Activities

Member, residency selection committee: Participate in interviews of ~50 resident applicant per year; ensure diversity of those selected to match (our current resident includes majority identifying as women).

Principal investigator and Branch Chief: Leading a laboratory team that is comprised of predominantly PhD scientists, ensuring diversity (50% members identifying as women); branch chief of >100-memebr team, ensuring that diversity is a key factor in hiring and promotion decisions.

Contribution to Science

1. Clinically relevant genomic subtypes of brain tumors.

Using global gene expression profiling, methylation profiling and other modalities we established the concept of glioma transcriptomal subtypes, as well as defining relevant biological subtypes of meningioma.

a) Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, Ozburn N, Chen M, Pan E, Koul D, Yung WK, Feuerstein BG, Aldape KD. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res. 2005 Mar;65 (5):1678-86. PMID: 15753362

b) Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006 Mar;9 (3):157-173. PMID: 16530701

c) Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K, Cancer Genome Atlas Research Network. Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma. Cancer Cell. 2010 May;17 (5):510-522. e-Pub 4/2010. PMCID: PMC2872684

d) Nassiri F, Liu J, Patil V, Mamatjan Y, Wang JZ, Hugh-White R, Macklin AM, Khan S, Singh O, Karimi S, Corona RI, Liu LY, Chen CY, Chakravarthy A, Wei Q, Mehani B, Suppiah S, Gao A, Workewych AM, Tabatabai G, Boutros PC, Bader GD, de Carvalho DD, Kislinger T, Aldape K*, Zadeh G*.. A clinically applicable integrative molecular classification of meningiomas. Nature. 2021 Sep;597 (7874):119-125. doi: 10.1038/s41586-021-03850-3. *co-senior authors. PMID: 34433969

2. Use of DNA methylation profiles to classify and prognosticate brain tumors.

The future of tumor classification will incorporate molecular tools to classify and diagnose neoplastic entities more precisely in the clinic. We are part of ongoing studies to develop and implement genome-wide methylation patterns to improve diagnostic accuracy of brain tumors (work with DKFZ, Heidelberg, Germany). Additional specific applications include applying a methylation signatures in tumor samples and blood to guide treatment decisions in aggressive meningiomas, as well as using modern molecular techniques to understand and characterize nerve sheath tumors.

a) Capper D, et al. including Aldape K… , DNA methylation-based classification of central nervous system tumours. Nature. 2018 Mar 22;555 (7697):469-474. PMCID: PMC6093218

b) Agnihotri S, Suppiah S, Tonge PD, Jalali S, Danesh A, Bruce JP, Mamatjan Y, Klironomos G, Gonen L, Au K, Mansouri S, Karimi S, Sahm F, von Deimling A, Taylor MD, Laperriere NJ, Pugh TJ, Aldape KD*, Zadeh G*. Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas. Nature Communications. 2017 Aug 4;8 (1):186. *Co-corresponding authors. PMCID: PMC5543118

c) Agnihotri S, Jalali S, Wilson MR, Danesh A, Li M, Klironomos G, Krieger JR, Mansouri A, Khan O, Mamatjan Y, Landon-Brace N, Tung T, Dowar M, Li T, Bruce JP, Burrell KE, Tonge PD, Alamsahebpour A, Krischek B, Agarwalla PK, Bi WL, Dunn IF, Beroukhim R, Fehlings MG, Bril V, Pagnotta SM, Iavarone A, Pugh TJ, Aldape KD*, Zadeh G*. The genomic landscape of schwannoma. Nature Genetics. 2016 Nov;48 (11):1339-1348. *Co-corresponding authors. PMID: 27723760

d) Wu Z, Abdullaev Z, Pratt D, Chung HJ, Skarshaug S, Zgonc V, Perry C, Pack S, Saidkhodjaeva L, Nagaraj S, Tyagi M, Gangalapudi V, Valdez K, Turakulov R, Xi L, Raffeld M, Papanicolau-Sengos A, O’Donnell K, Newford M, Gilbert MR, Sahm F, Suwala AK, von Deimling A, Mamatjan Y, Karimi S, Nassiri F, Zadeh G, Ruppin E, Quezado M, Aldape K. Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics. Neuro Oncol. 2021 Sep 23: noab227. PMCID: PMC8972234

e) Olar A, Wani KM, Wilson CD, Zadeh G, DeMonte F, Jones DT, Pfister SM, Sulman EP, Aldape KD. Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. Acta Neuropathol. 2017 Mar;133(3):431-444. PMCID: PMC5600514

3. WHO classification of CNS tumors.

I have been a member of the core group to update and develop classification criteria for the diagnosis of central nervous system tumors. I contribute chapters to the 2007 and 2016 updates, and am a member of the cIMPACT-NOW group, which provides continuous recommendations for updates for brain tumor classification.

a) Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Cairncross JG, Pfister SM, Rutkowski S, Weller M, Wick W, von Deimling A. Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathol. 2017 Jan;133 (1):1-3. PMID: 27909809

b) Aldape K, Nejad R, Louis DN, Zadeh G. Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community. Neuro Oncol. 2017. PMCID: PMC5464323

c) Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, Aldape K, Brat D, Collins VP, Eberhart C, Figarella- Branger D, Fuller GN, Giangaspero F, Giannini C, Hawkins C, Kleihues P, Korshunov A, Kros JM, Beatriz Lopes M, Ng HK, Ohgaki H, Paulus W, Pietsch T, Rosenblum M, Rushing E, Soylemezoglu F, Wiestler O, Wesseling P. International Society Of Neuropathology -Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 2014 Sep;24 (5):429-35. PMCID: PMC8029490

d) Multiple authors, including Aldape K. WHO Classification of Tumours of the Central Nervous System (IARC WHO Classification of Tumours); World Health Organization; Revised edition (2021).

Complete List of Published Work in MyBibliography:

Full list of published work (~600 publications in PubMed)
https://www.ncbi.nlm.nih.gov/pubmed/?term=aldape+k

1985年3月	東京医科歯科大学医学部　卒業
1985年6月	東京医科歯科大学医学部付属病院脳神経外科　研修医
1989年10月	東京医科歯科大学医学部脳神経外科　助手
1991年10月	スウェーデン　ヨテボリ大学大学院病理研究科　研究員
1994年6月	スウェーデン　カロリンスカ研究所大学院　腫瘍病理研究科入学
1996年6月	スウェーデン　カロリンスカ研究所大学院　腫瘍病理研究科修了（医学博士）
1996年7月	スウェーデン　ルードヴィク癌研究所ストックホルム支部　Postdoctoral fellow
1998年7月	英国ケンブリッジ大学病理学部 上級研究員
2006年7月	英国ケンブリッジ大学病理学部分子病理科　主任研究員
2011年10月	国立がん研究センター研究所　脳腫瘍連携研究分野　分野長
2019年9月	神戸大学客員教授（兼任、現在に至る）
2020年6月	順天堂大学客員教授（兼任）
2021年4月	順天堂大学医学部　脳疾患連携分野研究講座　特任教授
2024年4月	杏林大学医学部　病理学教室　特任教授

専門

分子腫瘍学、神経腫瘍学

資格

医師免許（第288901号、昭和60年5月21日）
医学博士（Ph.D., Faculty of Medicine, Karolinska Institute, 1996年6月6日）

受賞歴

1997年	Young Investigator Award, 第88回アメリカ癌学会総会（サンディエゴ、USA）
2005年	Samantha Dickson Research Trust Award for Scientific Research Excellence、第2回国際脳腫瘍学会、エジンバラ、UK
2018年	日本政府観光局（JNTO）国際会議誘致・開催貢献賞誘致の部　受賞

学会活動等

The 24th International Conference on Brain Tumor Research and Therapy（ICBTRT 2025）会長
第19回国際小児脳腫瘍シンポジウム（ISPNO2020）会長
日本脳腫瘍学会理事
日本癌学会評議員
アメリカ癌学会正会員
関東小児脳腫瘍カンファレンス世話人
日本脳神経外科学会会員／日本脳腫瘍病理学会会員／日本小児血液・がん学会会員
Neuro-Oncology Executive Editor
Acta Neuropathologica Editorial Board
Cancer Science Associate Editor